Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy? - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Gastroenterology Année : 2014

Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?

Résumé

We read with great interest the paper by Panes et al1 regarding the efficacy of early azathioprine (AZA) therapy in early Crohn’s disease (CD). The “AZathioprine for Treatment or Early Crohn’s disease in adults” (AZTEC) study was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial conducted in 31 Spanish hospitals over 3 years. The authors developed a randomized placebo-controlled trial in very early CD patients (<8 weeks of diagnosis) without bowel damage (symptomatic stenotic, penetrating, or perianal disease).

Dates et versions

hal-01687303 , version 1 (18-01-2018)

Identifiants

Citer

Peter Lakatos, Laurent Peyrin-Biroulet. Azathioprine in Early Crohn’s Disease: Time to Revisit Patient Selection and End Points for Clinical Trials and/or Azathioprine Efficacy?. Gastroenterology, 2014, 146 (3), pp.867 - 868. ⟨10.1053/j.gastro.2013.11.053⟩. ⟨hal-01687303⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More